Screening therapeutic antibody candidates for complement-dependent activity can be crucial in developing successful biologicals. Take advantage of Horizon´s extensive cell line library and challenge your compounds in a semi-automated manner and progress with confidence
What is a Complement-Dependent Cytoxicity (CDC) assay?
Complement-dependent cytotoxicity (CDC) is an immune response in which target cells are lysed through activation and recruitment of the complement cascade to the targeted cell surface. The CDC is a tightly regulated process, where several therapeutic monoclonal antibodies leverage the power of the membrane attack complex to lyse cancerous cells.
There are many reasons why the CDC assay could be a good option for your project
The CDC assay supports the validation of therapeutic antibodies for cancer immunotherapy to confirm complement-dependent effectiveness. The lead therapeutics compounds can be screened in model cancer cell lines to identify the mechanism of action. Moreover, screening of therapeutic candidates in a broader OncoSignature™ panel of cancer cell lines can expand the applications of your lead compound in other cell types or tissues.
Horizon's CDC assay
Our CDC assay allows screening of a panel of compounds in a model cancer cell line to identify candidate lead compounds for more advanced studies. Alternatively, screen a few lead compounds in a cancer cell line panel to test lead compounds' effectiveness in different cell types/tissues.
- Rapid and robust data of your compounds’ cytotoxic activity from an in vitro setting
- Short project completion – from 5-6 weeks (dependent on cell growth)
- Screen panel of candidate therapeutics in model cell lines
- Validate lead therapeutics in OncoSignature™ cancer cell line panel
The CDC assay is a powerful screening platform to aid the development of successful therapeutic mAbs. Here, we have developed a robust CDC assay workflow incorporating semi-automation, which accurately and reproducibly supports the testing and comparison of mAbs candidates across a panel of cancer cell lines. Leveraging OncoSignature™ cell line panel, we can apply our CDC assay workflow to test mAbs targeting a broad range of surface proteins with various expression levels, thus ensuring that candidate mAbs can be validated across several cell lines and lineages.